Stockscreener 앱 받기
3.57
0.28%
0.010
시간 외 거래:
3.58
0.01
+0.28%
전일 마감가:
$3.56
열려 있는:
$3.5
하루 거래량:
4.96M
Relative Volume:
1.16
시가총액:
$1.30B
수익:
$3.06M
순이익/손실:
$-141.62M
주가수익비율:
-4.8552
EPS:
-0.7353
순현금흐름:
$-78.67M
1주 성능:
-6.54%
1개월 성능:
-6.54%
6개월 성능:
-27.88%
1년 성능:
+156.83%
1일 변동 폭
$3.45
$3.645
1주일 범위
$3.45
$3.90
52주 변동 폭
$1.15
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
명칭
Ataibeckley Inc
전화
49 89 2153 9035
주소
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.57 | 1.29B | 3.06M | -141.62M | -78.67M | -0.7353 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-07-29 | 개시 | Oppenheimer | Outperform |
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Ataibeckley Inc 주식(ATAI)의 최신 뉴스
AtaiBeckley Advances BPL-003 Program As Beckley Psytech Deal Closes - simplywall.st
AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish (NASDAQ:ATAI) - Seeking Alpha
Assessing AtaiBeckley (ATAI) Valuation As Strong Long Term Returns Contrast With Heavy Losses - Yahoo Finance
AtaiBeckley: Advancing BPL-003 Into Pivotal Phase 3 With Strategic Optionality and Strong Cash Runway Supporting a Buy Rating - TipRanks
H.C. Wainwright reiterates atai Life Sciences stock rating at buy - Investing.com
H.C. Wainwright reiterates atai Life Sciences stock rating at buy By Investing.com - Investing.com UK
AtaiBeckley publishes Phase 2a data for depression treatment By Investing.com - Investing.com South Africa
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN
Weighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility - simplywall.st
Small cap wrap: AtaiBeckley, New Era Energy & Digital, Standard Uranium, Namibia Critical Metals… - Proactive Investors
H.C. Wainwright Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
AtaiBeckley sees promising mid-stage results for psychedelic antidepressant - Seeking Alpha
AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003 - Proactive financial news
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation - Bitget
AtaiBeckley publishes Phase 2a data for depression treatment - Investing.com India
AtaiBeckley Inc. Publishes Positive Phase 2a Study Results of BPL-003 for Treatment-Resistant Depression in Journal of Psychopharmacology - Quiver Quantitative
Single-dose nasal spray eases treatment-resistant depression in 12-patient trial - Stock Titan
ATAI: HC Wainwright & Co. Reiterates Buy Rating with Maintained $25 Price Target | ATAI Stock News - GuruFocus
Atai Beckley NV (ATAI) is a buy on mental therapeutics opportunities - MSN
symbol__ Stock Quote Price and Forecast - CNN
AtaiBeckley plans Phase 3 trials for depression treatment in Q2 By Investing.com - Investing.com Nigeria
Why AtaiBeckley (ATAI) Is Up 10.0% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st
Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published - Psychedelic Alpha
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise - TradingView
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise in mental health - TradingView
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting, AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - marketscreener.com
H.C. Wainwright Maintains Buy on ATAI Atai Beckley N.V Mar 2026 - Meyka
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
AtaiBeckley plans Phase 3 trials for depression treatment in Q2 - Investing.com South Africa
4 Analysts Have This To Say About AtaiBeckley - Sahm
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day - Yahoo Finance
AtaiBeckley Social Anxiety Treatment A Game-Changer: AnalystsAtaiBeckley (NASDAQ:ATAI) - Benzinga
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - Investing News Network
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Atai Beckley N.V. (ATAI) and Artivion (AORT) - The Globe and Mail
Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting - TipRanks
AtaiBeckley Inc. Advances BPL-003 toward Phase 3 Trials for Treatment-Resistant Depression Following Positive Phase 2b Results - Quiver Quantitative
AtaiBeckley nasal spray for hard-to-treat depression eyes 2026 trials - Stock Titan
Assessing Atai (ATAI) Valuation After FDA Backing For BPL-003 And Positive EMP-01 Trial Results - simplywall.st
AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate - marketscreener.com
Atai Life Sciences Stock Poised for Gains Amid New FDA Trials Approval - timothysykes.com
FDA Supports AtaiBeckley’s New Depression Treatment Trials - StocksToTrade
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal - Psychedelic Alpha
AtaiBeckley’s FDA Backing And Trial Data Reframe Mental Health Upside And Risk - Yahoo Finance
AtaiBeckley Files For Mixed Shelf Offering - TradingView
Atai Beckley Inc (ATAI) has filed documents with the U.S. Securities and Exchange Commission (SEC) to allow selling shareholders to resell up to 74.3 million ordinary shares. - Bitget
AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg - MSN
Ataibeckley Inc (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):